1Matsubara T,Ichiyama T,Furufawa S.Immunological profile of peripheral boold lymphocytes and monocytes/macrophages in Kawasaki disease[J].Clin Exp Immunol,2005,141(3):381-387.
2Newburger JW,Takahashi M,Gerber MA,et al.Diagnosis,treatment,and long-term management of Kawasaki disease:a statement for health professionals from the Committee on Rheumatic Fever,Endocarditis,and Kawasaki Disease,Council on Cardiovascular Disease in the Young,American Heart Association[J].Pediatrics,2004,114(6):1708-1733.
3Fong NC,Hui YW,Li CK,et al.Evaluation of the efficacy of treatment of Kawasaki disease before day 5 of illness[J].Pediatri Cardiol,2004,25(1):31-34.
4Muta H,Ishii M,Egami K,et al.Early intravenous gamma-globulin treatment for Kawasaki diseasethe nationwide surveys in Japan[J].J Pediatr,2004,144(4):496-499.
5Terai M,Shulman ST.Prevalence of coronary artery abnormalities in Kawasaki disease is highly dependent on gamma globulin dose but independent of salicylate dose[J].J Pediatr,1997,131(6):888-893.
6Yeo JS,Choi JW.Effectiveness of Medium-Dose Intravenous Immunoglobulin(1 g/kg)in the Treatment of Kawasaki Disease[J].Korean Circ J,2010,40(2):81-85.
7Fury W,Tremoulet AH,Watson VE,et al.Transcript abundance patterns in Kawasaki disease patients with intravenous immunoglobulin resistance[J].Hum Immunol,2010,71(9):865-873.
9Inoue Y,Okada Y,Shinohara M,et al.A multicenter prospective randomized trial of corticosteroids in primary therapy for Kawasaki disease:clinical course and coronary artery outcome[J].J Pediatr,2006,149(3):336-341.
10Athappan G,Gale S,Ponniah T.Corticosteroid therapy for primary treatment of Kawasaki disease-weight of evidence:a meta-analysis and systematic review of the literature[J].Cardiovasc J Afr,2009,20(4):233-236.
